The head and neck cancer immune landscape and its immunotherapeutic implications.


Recent clinical trials have demonstrated a clear survival advantage in advanced head and neck squamous cell carcinoma (HNSCC) patients treated with immune checkpoint blockade. These emerging results reveal that HNSCC is one of the most promising frontiers for immunotherapy research. However, further progress in head and neck immuno-oncology will require a… (More)

5 Figures and Tables


  • Presentations referencing similar topics